Gastroesophageal reflux in mature neonate. Other specified perinatal digestive system disorders
Conditions
Interventions
Intervention 1: In group 1 intervention: Ranitidine 2 mg/kg TDS plus metoclopramide 0/15 mg/kg TDS for one month. Intervention 2: In group 2 intervention: lansoprazole 0/7 mg/kg/BID plus metoclopramid
Treatment - Drugs
In group 1 intervention: Ranitidine 2 mg/kg TDS plus metoclopramide 0/15 mg/kg TDS for one month
In group 2 intervention: lansoprazole 0/7 mg/kg/BID plus metoclopramide 0/15 mg/kg TDS for one month.
Sponsors
Investigator
Eligibility
Sex/Gender
All
Age
1 Days to 30 Days
Inclusion criteria
Inclusion criteria: Healthy term neonates aged 1–30days with GERD not responding to conservative therapies including antireflux positioning, milk thickening, hypoallergic regimens and monotherapy.
Exclusion criteria
Exclusion criteria: 1-Neonates with any underlying diseases, including anomalies or gastrointestinal obstruction, neurological disorders, sepsis, NEC, etc.2-Using any sedative , relaxant or anticonvulsive medications .3-History of ventilation therapy.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The rate of complications of ranitidine , lanzoprasole and omeprazole in each group of intervention. Timepoint: One week and one month after beginning of intervention. Method of measurement: Questionnaire. | — |
Primary
| Measure | Time frame |
|---|---|
| The response rate of GERD symptoms and signs in each intervention group. Timepoint: One week and one month after beginning of intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Peymaneh Alizadeh Taheri
Tehran University of Medical Sciences, Bahrami Hospital
Outcome results
None listed